Brought to you by 
Tornier gets rights to BioSET's F2A synthetic growth factor
23 Jun 2022
Executive Summary
Tornier has received exclusive worldwide rights to develop, commercialize, and distribute products that incorporate fellow orthopedic device firm BioSurface Engineering Technologies's F2A synthetic growth factor technology.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tornier gets rights to BioSET's F2A synthetic growth factor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice